patritumab

A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds… (More)

Topic mentions per year

Topic mentions per year

2014-2018
024620142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Integrating molecularly targeted agents with cytotoxic drugs used in curative treatment of pediatric cancers is… (More)
  • table 1
Is this relevant?
2016
2016
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Human epidermal growth factor receptor 3 (HER3) expression in lung and breast cancers has a negative impact on survival… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2016
Review
2016
INTRODUCTION The mutation or expression of HER family members serves as a therapeutic target for tyrosine kinase inhibitors or… (More)
Is this relevant?
2016
2016
This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2015
2015
The purpose of this study was to evaluate the safety, dosimetry, and apparent receptor occupancy (RO) of [64Cu]DOTA-patritumab, a… (More)
  • table 2
  • table 3
  • figure 1
Is this relevant?
2015
2015
OBJECTIVES Human epidermal growth factor receptor 3 (HER3) is a key dimerization partner for HER family members and is associated… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2015
2015
BACKGROUND During early clinical development, prospective identification of a predictive biomarker and validation of an assay… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2014
2014
We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Patritumab (U3-1287) is a human epidermal growth factor receptor-3 (HER3)-targeted antibody that blocks ligand-associated… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?